The New Counter-UAS Systems Market
18 September 2026.Counter-UAS procurement shifts towards integrated systems, common standards and scale
Counter-UAS procurement shifts towards integrated systems, common standards and scale
Specialist pharma capacity remains constrained by format, qualification and demand
Small drones are reshaping defence through layered, affordable counter-UAS strategies
Commercial site transfers reshape CDMO growth, revenue timing and value
Britain tests faster counter-drone procurement as lasers and integration advance
Faster trials increase demand for flexible, resilient clinical supply networks
Australia’s defence build-up tests industry, supply chains and delivery capacity
US pharma investment shifts toward strategic, complex, domestic manufacturing capacity
Washington expands missile production, but rebuilding depleted inventories takes years
CDMO competition shifts toward specialist capacity, geography and selective outsourcing
The global Clinical Trial Supply and Logistics Market for Pharma is projected to grow at a CAGR of 8.7% by 2036
The global Macular Degeneration (AMD) and Other Retinal Diseases Drugs market is projected to grow at a CAGR of 9.0% by 2036
The global market is expected to expand from US$9.91bn in 2026 to US$41.58bn by 2036, at a 15.4% CAGR
Washington targets critical material dependencies across batteries, bauxite and magnets
The global market is expected to expand from US$75.67bn in 2026 to US$257.09bn by 2036, at a 13.0% CAGR
Moderna’s flu approval tests whether mRNA can deliver commercial scale
The global market is expected to expand from US$43.70bn in 2026 to US$166.36bn by 2036, at a 14.3% CAGR
The global market is expected to expand from US$142.55bn in 2026 to US$459.75bn by 2036, at a 12.4% CAGR
The global market is expected to expand from US$32.28bn in 2026 to US$117.20bn by 2036, at a 13.8% CAGR
Washington targets missile and drone bottlenecks across critical defence supply chains